0000109657 2026-04-30 2026-04-30 0000109657 1 2026-04-30 2026-04-30 0000109657 1 2026-04-30 2026-04-30 0000109657 2 2026-04-30 2026-04-30 iso4217:USD pure shares S-1 S-1 EX-FILING FEES 0000109657 GT Biopharma, Inc. N/A true false S-1 GT Biopharma, Inc. false Equity Common Stock, par value $0.001 per share true 9723057 0.28 2722455.96 0.0001381 375.97 2722455.96 375.97 0.00 350.15 25.82 (1) Represents shares of Common Stock, par value $0.001 per share ("Common Stock"), of GT Biopharma, Inc. (the "Company"), which consists of (i) 4,527,654 shares of Common Stock issuable upon the conversion of 2,055.5554 shares of Series L 10% Convertible Preferred Stock, par value $0.001 per share (the "Series L Preferred Stock"), (ii) 4,527,654 shares of Common Stock issuable upon the exercise of vested warrants issuable upon exercise of the Greenshoe Rights (as defined in the Registration Statement), (iii) 267,749 shares of Common Stock issued to the holders of Series L Preferred Stock of record as of March 19, 2026 as a dividend, which represents 10% of the outstanding stated value of the Series L Preferred Stock, payable on April 1, 2026, and (iv) 400,000 shares of Common Stock issuable upon the exercise of pre-funded warrants, offered for resale by the selling stockholders pursuant to the prospectus contained in this Registration Statement on Form S-1. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of common stock issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction. (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based on the average of the high and low prices of the registrant's Common Stock on April 28, 2026, as reported on The Nasdaq Capital Market. true S-1 333-287963 2025-06-11 350.15 true GT Biopharma, Inc. S-1 333-287963 2025-06-11 350.15 (3) The Company previously paid $20,523.20 with respect to 9,055,308 shares of Common Stock included herein based on a maximum aggregate offering price of $131,368,755.03 in connection with its filing of the Registration Statement on Form S-1 (File No. 333-287963) on June 11, 2025 in connection with the Private Placement (as defined in the Registration Statement). In accordance with Rule 457(b) under the Securities Act, the Company is using $350.15 of the previously paid fees to offset the filing fee payable in connection with this amendment to this Registration Statement.